Chronic
Remibrutinib potential first-in-class oral treatment for chronic spontaneous urticaria
Positive top-line results from two phase 3 studies show remibrutinib yielded statistically significant improvements in disease severity among patients with chronic spontaneous urticaria, Novartis announced in a press release.
Diagnose dry eye in a few simple steps
Even if your practice is pressed for time, you have time to diagnose dry eye disease, treat it and track your results. Diagnosis doesn’t take a lot of extra equipment — just simple steps you can fit into a basic exam.
Gusacitinib shows promise as treatment for chronic hand eczema
Gusacitinib significantly outperformed placebo, showing a tolerable safety profile and a rapid improvement in the treatment of patients with chronic hand eczema, according to a phase 2 study.
Delgocitinib safe, efficacious in chronic hand eczema
NEW ORLEANS — Phase 3 trial results found delgocitinib cream to significantly improve patient and clinician-reported outcomes of hand eczema, according to a presenter at the American Academy of Dermatology Annual Meeting.
New phase 3 data confirm prior positive findings of delgocitinib for chronic hand eczema
The DELTA 2 pivotal phase 3 clinical trial showed positive topline results for the use of delgocitinib cream in adults with moderate to severe chronic hand eczema, LEO Pharma announced in a press release.
Positive phase 3 results reported for delgocitinib cream for chronic hand eczema
Delgocitinib cream met the primary endpoint in the DELTA 1 pivotal phase 3 clinical trial for the treatment of moderate to severe chronic hand eczema in adults, according to a press release from Leo Pharma.
Risk and rate of accumulating chronic conditions increases with depression, anxiety
The risk and rate of accumulating chronic conditions increased with diagnoses of depression and anxiety for both men and women, according to a study published in JAMA Network Open.
Itraconazole for chronic pulmonary aspergillosis: Longer is better
A randomized controlled trial in India demonstrated that 12 months of oral itraconazole was superior to a 6-month regimen in reducing relapses of chronic pulmonary aspergillosis, researchers reported in The Lancet Infectious Diseases.
Omalizumab effectively treats chronic cold urticaria
Omalizumab effectively treated chronic cold urticaria and prevented further episodes of anaphylaxis, according to a single-center study published in The Journal of Allergy and Clinical Immunology: In Practice.
Occipital nerve stimulation safely reduces frequency of chronic cluster headache
Occipital nerve stimulation significantly reduced attack frequency and was safe and well-tolerated in patients with medically intractable chronic cluster headaches, according to a study published in Lancet Neurology.